Terapi Kortikosteroid Sistemik untuk Sindrom Steven Johnson (SSJ)- Nekrolisis Epidermal Toksik (NET) di RSUD DR Moewardi, Surakarta, Indonesia - Eka Devinta Novi Diana; Rakhma Tri Irfanti; Alfina Rahma; Frieda -; Wibisono Nugraha; Muhammad Eko Irawanto (Cermin Dunia Kedokteran, 2021)
Latar belakang :Sindrom Steven Johnson (SSJ) dan nekrolisis epidermal toksik (NET) adalah manifestasi reaksi alergi obat paling berat dan mengancam jiwa yang dimediasi sel T. Salah satu terapi SSJ-NET yaitu kortikosteroid sistemik. Tujuan : Mengetahui pola terapi kortikosteroid sistemik di Instalasi Rawat Inap RSUD Dr. Moewardi Surakarta periode Januari 2014-Desember 2018. Metode : Penelitian deskriptif retrospektif atas data rekam medis pasien SJS-NET di Instalasi Rawat Inap RSUD Dr. Moewardi Surakarta periode Januari 2014-Desember 2018. Hasil : Didapatkan 80 pasien SJS-NET, usia terbanyak 46-65 tahun (39%), lebih banyak laki-laki (52%). Diagnosis SSJ paling banyak (61%) dibandingkan SSJ overlap NET (24%) maupun NET (15%) dengan keterlibatan mukosa mulut terbanyak (64%). Penyakit penyerta terbanyak adalah diabetes melitus (18 %). Penyebab SSJ-NET terbanyak diduga lebih dari satu obat (44%). Terapi kortikosteroid sistemik berupa injeksi metilprednisolon dengan rata-rata dosis 65 mg/hari dan lama perawatan 10 hari. Simpulan :Kortikosteroid sistemik merupakan terapi semua kasus SSJ-NET di RSUD dr. Moewardi Surakarta.Background: Steven Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are the severest primarily T-cell mediated manifestation and life threatening drug reaction. Systemic corticosteroid is used for SJS-TEN management. Objective: To study the pattern of systemic corticosteroid therapy for SJS-TEN in Dr.Moewardi General Hospital Surakarta Januari 2014-December 2018. Method: A descriptive retrospective study on medical record data of SJS-TEN patients hospitalized at Dr.Moewardi General Hospital Surakarta between January 2014 and December 2018. Results: From a total 80 SJS–TEN patients in this study, 39% was 46-65 year-old, male (52%). The most frequent diagnosis was SJS (61%) followed by SJS overlap TEN (24%) and TEN (15%), mostly with mucosal mouth involvement (64%). The most frequent comorbidities was DM (18%). More than one drug were related to SJS-TEN (44%). Therapy for all cases was systemic corticosteroids with an average dose of methylprednisolone 65 mg per day in 10 days. Conclusion :Systemic corticosteroids was used in all cases of SSJ-NET in Dr.Moewardi General Hospital Surakarta.